

# COVID-19: VACCINE DEVELOPMENT, ACCESS AND DELIVERY

---

BOARD MEETING

**Aurélia Nguyen**

24-25 June 2020, Virtual Meeting



Reach every child

[www.gavi.org](http://www.gavi.org)

# Agenda


---

- Access to COVID-19 Tools Accelerator (ACT-A)
- COVID-19 Vaccines Global Access (COVAX) Facility
- Gavi COVAX Advance Market Commitment (AMC)
- Considerations for delivery-at-scale of future COVID-19 vaccines
- Cold chain capacity needs for COVID-19 vaccines

# ACT- Accelerator Vaccine Pillar


## Facilitation Council Group

### Access to COVID-19 Tools Accelerator (ACT-A)




## COVAX Coordination Meeting (CCM)

### Vaccine Pillar



# The Vaccine pillar of the ACT-A takes end-to-end view from R&D to delivery

---



## COVAX Facility open to all countries and all COVID-19 vaccines

- CEPI portfolio already 9 vaccines but need to build inventory
- Currently 2<sup>nd</sup> call for proposal for more candidates

# The COVID-19 Vaccine Global Access (COVAX) Facility enables global collaboration and equitable access to vaccines

## Context and Issue

- **National and regional initiatives** prioritising supply for domestic population over global health needs
- **Competition for candidates** – bidding frenzy
- **Inequitable access to vaccines** – only accessible by countries that selected successful candidates
- **Countries without financial resources left behind**
- **Inefficient use of resources**



## Solution: COVAX Facility

**A globally coordinated mechanism for financing and procurement is required to accelerate equitable access to appropriate, safe and efficacious vaccines**


### **Supporting objectives:**

- Secure supply rapidly through resilient scale-up of manufacturing
- Reduce uncertainty and lack of predictability of demand and financing as a barrier to manufacturing expansion



# The COVID-19 Vaccine Global Access (COVAX) Facility enables global collaboration and equitable access to vaccines

The COVAX Facility is administered by the Gavi Secretariat and implemented in partnership with ACT Accelerator actors




*1 Agreements with manufacturers would be unified across full scope of countries participating in the Facility, but ODA funding will only be used to support LICs and LMICs*

*2 Financing for procurement incremental to contribution*

# Gavi COVAX AMC is an innovative finance instrument within the Facility focused on securing Vaccine access for LICs/LMICs

Gavi COVAX AMC was launched on June 4 and is the first building block of the COVAX Facility



## Financing the Gavi COVAX AMC

- Seed funding ask of US\$ 2 billion to secure doses for LICs/LMICs<sup>2</sup>
- 4 June launch, with over US\$ 500 million raised – primarily ODA from OECD countries

## Access to COVAX doses

- LICs/LMICs get access to vaccines as soon as they become available to vaccinate highest priority populations
- Doses allocated based on WHO's global allocation framework

# Considerations for delivery at-scale of future COVID-19 vaccines

## Programme design and country readiness

**Strong coordination** to ensure **vaccine characteristics**, **SAGE recommendations** and **policy guidance** are appropriate to meet the programmatic realities of Gavi countries

Efforts underway to develop:

- Vaccine programme objectives, **delivery** and **use scenarios**
- Operational guidance materials and tools
- **Costing** and **funding requirements**

Provide timely support to address **absorptive capacity challenges** (e.g. **HR capacity**, **gov't advocacy**, **vaccine acceptance**, **cold chain**, etc.)

## Unique challenges and uncertainties



***Vaccine characteristics***



***Targeting unique sub-populations  
(Healthcare workers, elderly, etc.)***



***Regulatory, Safety Monitoring,  
Indemnification***



# Delivery of COVID-19 vaccines may require significant and urgent ramp-up of cold chain capacity

- Gavi leading inter-agency effort on CCE as part of ACT-A HSS connector
- Recommendation to **use CCEOP to address cold chain needs for all COVID-19 commodities of 78 LICs / LMICs and 12 IDA-eligible small economies**
  - Potentially significant **additional investments** (~US\$ 40-140 million for HSS-supported countries until 2025; additional US\$ ~85 million to US\$ ~200 million if expand to the 90 countries) in CCE required **for COVID-19 vaccine delivery – suppliers could likely meet demand** within few months but **need a clear demand signal**
  - Expanding support to **cover cold chain needs for COVID-19 diagnostics and therapeutics** may require **only limited** incremental CCE **capacity**
- Request for guidance on opportunity to **leverage CCEOP** to provide cold storage capacity **for other PHC commodities** (e.g. oxytocin, insulin) and drive **health facility solarisation**

# Recommendation (1 of 2)

---

The Gavi Alliance Board is requested to:

- a) With respect to the COVAX Facility:
  - i. **Note** that the COVAX Facility is proposed as a time-limited global, coordinated mechanism designed to ensure rapid and equitable access to a safe and efficacious COVID-19 vaccine to as broad a global population as possible and that without such a mechanism, manufacturers may not expand production capacity to adequately address the global pandemic, leaving behind vulnerable populations across the globe and in particular those in the lower income countries served by Gavi;
  - ii. **Note** that the Gavi Secretariat is acting as the administrator for the COVAX Facility to support its design and operationalisation and that the Secretariat will develop, for the Gavi Board's consideration, a more detailed description of Gavi's role in coordinating and operationalising the activities including how the Secretariat assumes liabilities on behalf of the COVAX Facility, as well as a tailored governance mechanism for the COVAX Facility;

# Recommendation (2 of 2)

---

- b) **Confirm** Gavi's role in supporting cold chain support for COVID-19 vaccines, diagnostics and treatments in 78 low and lower middle income countries and 12 IDA-eligible small economies, as agreed by the members of the ACT Accelerator, contingent on approval by the Board of a refined proposal to be developed by the Secretariat as described in Section 7 to Doc 05; and
  
- c) **Provide** guidance on the proposal to consider support to countries on cold chain needs across PHC commodities and to further explore the use of CCEOP as a platform for health facility solarisation as part of a co-investment model with other donors.

**Thank you**

---

